Retina

Experts in the field of retinal eye disorders discuss how the COVID-19 pandemic and use of telemedicine has affected communication between optometrists, ophthalmologists, patients, and providers.

Mark Packer, MD, shares his perspective on the relationship between ICL implantation or LASIK and retinal detachment.

Lower doses vs higher ones are equally effective for treating disease

Investigators have questioned the potential for the vascular density to be a biomarker for microvascular abnormalities following COVID-19 and found that longitudinal studies are needed to determine this.

According to the company, VVN001 demonstrated clinical and statistical superiority over vehicle in reducing total and sub-regional corneal fluorescein staining scores.

A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells – a class of neurons located in the retina that are critical for vision.

The company notes that its clinical trial of the light delivery system meets the primary efficacy endpoint, and can offer hope to patients with dry AMD who are experiencing vision loss and currently have limited treatment options.

Experts in the field of retinal eye disorders talk about the role of ophthalmologists and optometrists in regard to patient education and communication.

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss the American Academy of Ophthalmology (AAO) guidelines on co-management between optometrists and ophthalmologists in retinal eye disorders.

Provides safe, effective injection to target choroidal, retinal tissues

Jorge Calzada, MD, shares his use of MicroPulse laser technology to combat central serous retinopathy (CSR).

According to a team of investigators at University of California, Berkeley, tests of the drug Antabuse could prove the role of hyperactive retinal cells in blindness, potentially leading to better therapies.

Investigators find that hybrid cells could be a potential therapeutic strategy to treat retinal damage and visual impairment.

"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.

Researchers from the Department of Ophthalmology at the University Hospital Bonn and Deutsches Zentrum für Neurodegenerative Erkrankungen suggest that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy.” The findings are based on data from the Rhineland Study.

Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.

According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over.

Experts discuss the challenges regarding the treatment of retinal disorders, and how co-management can potentially address those challenges.

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss the co-management of retinal eye disorders and provide a clinical overview of the disease.

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.

Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”

Trial recruitment is enabled by the Foundation Fighting Blindness' patient registry, My Retina Tracker Registry, which includes gene

The clinical trial will evaluate the safety and tolerability of ADX-2191 in patients diagnosed with RP due to mutations of the rhodopsin gene, including the P23H gene mutation.

Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.

Christina Y. Weng, MD, MBA, an associate professor of ophthalmology and surgical retina fellowship program director at Baylor College of Medicine in Houston, recently shared some standout therapies for macular degeneration.

Aleksandra Rachitskaya, MD, discusses how the treatment landscape for inherited retinal diseases has changed and her hope for the future.

Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks, however it was safe and well tolerated with no new or unexpected safety signals.